Skip to main content
MaaT Pharma logo

MaaT Pharma — Investor Relations & Filings

Ticker · MAAT ISIN · FR0012634822 LEI · 969500CQQB6XUNW6CN97 PA Professional, scientific and technical activities
Open in API
Filings indexed 347 across all filing types
Latest filing 2023-03-02 Declaration of Voting R…
Country FR France
Listing PA MAAT

About MaaT Pharma

https://www.maatpharma.com/

MaaT Pharma is a clinical-stage biotechnology company specializing in the development of microbiome-based therapeutics. The company's primary focus is on oncology, aiming to improve survival outcomes for cancer patients by modulating the immune system through the gut microbiome. It develops Microbiome Ecosystem Therapies (MET) designed to restore gut microbiome symbiosis. The company's pipeline includes product candidates for treating complications in patients with blood cancers and solid tumors, with its lead candidate, MaaT013, in late-stage development for acute Graft-versus-Host Disease (aGvHD). MaaT Pharma utilizes an AI-powered platform for drug development and has its own cGMP manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital" and explicitly references French regulatory articles (AMF General Regulations, French Commercial Code) concerning the total number of shares and voting rights as of a specific date (February 28, 2023). This type of periodic disclosure detailing the capital structure and voting power is a specific regulatory requirement. It is not an Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). While it relates to share capital, it is a mandatory monthly disclosure of existing shares/rights, not a transaction like a share issue (SHA) or buyback (POS). It most closely aligns with a specific regulatory filing that reports on share structure, which falls under the general category of regulatory announcements or specific filings related to capital structure reporting. Given the options, this specific disclosure about the total number of voting rights and shares is a mandatory regulatory update. Since there isn't a specific code for 'Monthly Voting Rights Disclosure', and it is a formal regulatory announcement concerning share capital structure, it fits best under the general 'Regulatory Filings' (RNS) or potentially 'Share Issue/Capital Change' (SHA) if interpreted broadly, but RNS is the safer fallback for mandatory, non-financial periodic disclosures that don't fit elsewhere. However, looking closely at the definitions, it is a formal announcement of a key metric related to ownership/capital structure. Since it is a formal, periodic regulatory disclosure mandated by the AMF, RNS is the most appropriate general regulatory category.
2023-03-02 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital) and explicitly references French regulatory articles (Article 223-16 du Règlement Général de l'Autorité des Marchés Financiers, articles L. 233-8 II du code de commerce). It provides a table detailing the total number of shares and voting rights as of a specific date (28/02/2023). This type of mandatory periodic disclosure regarding the capital structure and voting rights is a specific regulatory filing, often required monthly or quarterly in European jurisdictions. Among the provided codes, this content most closely aligns with a general regulatory announcement or a specific filing related to share capital changes, which is covered by 'SHA' (Share Issue/Capital Change) or 'RNS' (Regulatory Filings - fallback). Since it is a formal, periodic disclosure of the total share count, it is a direct report on capital structure, making 'SHA' a strong candidate, although 'RNS' is also plausible if 'SHA' is reserved strictly for announcements of *new* issues/changes rather than periodic reporting of the current state. Given the explicit focus on the total number of shares and voting rights, which is a key component of capital structure reporting, 'SHA' is the most specific fit, although it is a periodic update rather than an announcement of a transaction. However, looking at the definitions, 'SHA' is for 'Share Issue/Capital Change'. A periodic disclosure of the total count is often categorized under general regulatory reporting. Since it is a formal, mandated disclosure that doesn't fit perfectly into the transactional 'SHA', and it is not an earnings release, management discussion, or proxy, the most appropriate general regulatory category is 'RNS'. If a more specific code existed for 'Share Capital Status Report', that would be chosen. Given the options, 'RNS' serves as the best fit for a mandatory, non-core financial report that details share structure.
2023-03-02 French
Franchissement de seuils
Major Shareholding Notification Classification · 99% confidence The document text explicitly states 'Déclaration de franchissement de seuils (article L. 233-7 du code de commerce)' which translates to 'Declaration of crossing thresholds'. It details that Symbiosis LLC crossed below the 20% threshold of capital and voting rights in MAAT PHARMA on February 21, 2023. This type of filing, reporting changes in significant share ownership that cross regulatory thresholds, directly corresponds to the Major Shareholding Notification category (MRQ). The document length is short (1226 chars), but the content is the declaration itself, not an announcement of a declaration.
2023-02-27 French
Franchissement de seuils et déclaration d'intention
Major Shareholding Notification Classification · 99% confidence The document is titled "Déclaration de franchissement de seuils et déclaration d'intention (article L. 233-7 du code de commerce)" and details that the company Biocodex crossed ownership thresholds (10% of capital and voting rights) in MAAT PHARMA on February 21, 2023. This type of mandatory filing, reporting changes in significant share ownership or crossing ownership thresholds, directly corresponds to the definition of Major Shareholding Notification (MRQ) in the provided schema, which covers notifications of changes in significant share ownership levels (crossing thresholds). The document is short and specific to this regulatory event.
2023-02-23 French
Franchissement de seuils et déclaration d'intention
Director's Dealing Classification · 98% confidence The document is titled "Déclaration de franchissement de seuils et déclaration d'intention (article L. 233-7 du code de commerce)" and details a change in shareholding percentage (crossing the 15% threshold) by Caisse des dépôts et consignations (CDC) in MAAT PHARMA. This type of mandatory disclosure regarding significant changes in ownership or control, often filed with regulatory bodies like the AMF (Autorité des marchés financiers) in France, corresponds directly to the definition of a Major Shareholding Notification, which is classified as 'MRQ' in the provided schema. The content is a formal notification of insider trading/ownership change, not a general regulatory filing (RNS) or a report itself.
2023-02-22 French
Franchissement de seuils et déclaration d'intention
Major Shareholding Notification Classification · 98% confidence The document is titled "Déclaration de franchissement de seuils et déclaration d'intention" (Declaration of crossing thresholds and declaration of intent) and explicitly references Article L. 233-7 of the French Commercial Code and AMF regulations. It details that Bpifrance crossed the 15% threshold of capital and voting rights in MAAT PHARMA. This type of mandatory filing, reporting changes in significant share ownership and stating future intentions, directly corresponds to the definition of Major Shareholding Notification (MRQ). The document is a formal regulatory disclosure regarding ownership changes, not a general regulatory announcement (RNS) or a report itself.
2023-02-22 French

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.